Kimathi Blackwood, MD
Nephrology · Macon, GANPI 1609071448
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,050 of the $64,004 with a category attached, or 70.4%. Amgen accounts for 81.5% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $25,151 and has fallen 56.7% since, to $10,882 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 451 payments — averaging $141.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$52K
- Calliditas Therapeutics US Inc.$4K
- AstraZeneca$756
- OPKO Pharmaceuticals, LLC$609
- Bayer$608
- Otsuka America Pharmaceutical, Inc.$600
- plus $5K from 33 others
What the payments were for
- Consulting fees$3,7006%
- Speaking & faculty fees$45,05070%
- Travel & lodging$4,0356%
- Food & beverage$10,46316%
- Education$7561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,004 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 25 | $939,776 |
| FarxigaDapagliflozin Propanediol | 259 | $261,713 |
| JardianceEmpagliflozin | 169 | $231,035 |
| KerendiaFinerenone | 233 | $179,519 |
| RayaldeeCalcifediol | 110 | $158,636 |
| FilspariSparsentan | 12 | $127,444 |
| BenlystaBelimumab | 16 | $103,581 |
| XphozahTenapanor Hcl | 22 | $98,041 |
| AuryxiaFerric Citrate | 23 | $63,922 |
| VeltassaPatiromer Calcium Sorbitex | 39 | $44,700 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $33,576 |
| EliquisApixaban | 23 | $25,586 |
| Sevelamer Carbonate | 57 | $23,322 |
| JanuviaSitagliptin Phosphate | 11 | $10,700 |
| Eplerenone | 48 | $4,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $52,177 | $939,77625 claims |
| AstraZenecaFarxiga, Lokelma | $756 | $295,289296 claims |
| Boehringer IngelheimJardiance | $75 | $231,035169 claims |
| BayerKerendia | $608 | $179,519233 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $609 | $158,636110 claims |
| Travere Therapeutics, Inc.Filspari | $498 | $127,44412 claims |
| GSKBenlysta | $498 | $103,58116 claims |
| Akebia Therapeutics IncAuryxia | $435 | $63,92223 claims |
| MerckJanuvia | $43 | $10,70011 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $309 | $78916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Macon
- Sagar PanseMacon$542K
- Reuben EllisMacon$27K
- Ahmad KabbaniMacon$16K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.